Nasdaq

QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer

therascreen® KRAS RGQ PCR kit approved as a companion diagnostic to aid in identifying non-small cell lung cancer (NSCLC) patients eligible for treatment with KRAZATI® (adagrasib) KRAS mutations in ...
Nasdaq

QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology

HILDEN, Germany & GERMANTOWN, Md. & KOBE, Japan--(BUSINESS WIRE)-- QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global strategic alliance with Japan’s Sysmex Corporation (Tokyo ...
Business Wire

QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug

QIAGEN has ten PCR based companion diagnostic indications that are FDA approved, including therascreen EGFR for non-small cell lung cancer (NSCLC), therascreen KRAS for colorectal cancer and NSCLC, ...